Association of APOE genotype with blood-brain barrier permeability in neurodegenerative disorders.

APOE genotype Albumin Blood-brain barrier Free light chains Kappa Lambda Permeability

Journal

Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437

Informations de publication

Date de publication:
10 Apr 2024
Historique:
received: 22 01 2024
revised: 06 04 2024
accepted: 07 04 2024
medline: 9 5 2024
pubmed: 9 5 2024
entrez: 8 5 2024
Statut: aheadofprint

Résumé

Apolipoprotein E (APOE) is recognized for its role in modulating blood-brain barrier (BBB) permeability in vitro, which may have significant implications for the pathogenesis and progression of neurodegenerative disorders. However, evidence in vivo is contrasting. This study explores the impact of APOE genotypes on BBB integrity among 230 participants experiencing cognitive impairment, encompassing cases of Alzheimer's disease (AD) as well as various non-AD neurodegenerative conditions. To assess BBB integrity, we utilized cerebrospinal fluid (CSF)/serum albumin ratios and CSF/serum kappa and lambda free light chains (FLCs) as indirect markers. Our findings show a dose-dependent increase in BBB permeability in individuals carrying the APOE ε4 allele, marked by elevated CSF/serum albumin and FLCs ratios, with this trend being especially pronounced in AD patients. These results highlight the association of APOE ε4 with BBB permeability, providing valuable insights into the pathophysiology of neurodegenerative diseases.

Identifiants

DOI: 10.1016/j.neurobiolaging.2024.04.003 PMID: 38718740
pubmed: 38718740
pii: S0197-4580(24)00075-7
doi: 10.1016/j.neurobiolaging.2024.04.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-40

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Auteurs

Ilenia Libri (I)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Chiara Silvestri (C)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Salvatore Caratozzolo (S)

Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili, Brescia, Italy.

Antonella Alberici (A)

Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili, Brescia, Italy.

Andrea Pilotto (A)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili, Brescia, Italy.

Silvana Archetti (S)

Biotechnology Laboratory and Department of Diagnostics, ASST Spedali Civili, Brescia, Italy.

Laura Trainini (L)

Biotechnology Laboratory and Department of Diagnostics, ASST Spedali Civili, Brescia, Italy.

Barbara Borroni (B)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Cognitive and Behavioral Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili, Brescia, Italy.

Alessandro Padovani (A)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili, Brescia, Italy; Brain Health Center, University of Brescia, Brescia, Italy.

Alberto Benussi (A)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Neurology Clinic, Department of Medicine, Surgery and Health Sciences, Trieste University Hospital, Trieste, Italy. Electronic address: benussialberto@gmail.com.

Classifications MeSH